S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Pulsed Dye Laser (PDL) Therapy in Adults

Phase 3

Completed

• Conditions: Pain
• Interventions: Drug: S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%); Drug: Placebo Peel

• Registration Number: NCT00110773
• Lead Sponsor: ZARS Pharma Inc.

Brief Summary

Pulsed dye laser (PDL) on the face is painful. For this reason, local anesthesia is commonly used to eliminate or minimize the pain. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate the efficacy of S-Caine Peel for induction of local dermal anesthesia for PDL therapy in adults.

Detailed Description

This was a multi-center (5 centers), double-blind, placebo-controlled, parallel study that included 80 adults who met all the eligibility criteria and who were undergoing PDL therapy for the treatment of vascular lesions on the face.

During the screening visit, the study, including potential risks and benefits, was clearly explained to each patient, and written informed consent was obtained from each patient. The screening visit also included: evaluating eligibility criteria, obtaining a medical history (including skin type, demographic data, and concomitant medications), a brief physical examination, and a urine pregnancy test (for women of childbearing potential). The screening visit could be completed on the same day as the procedure visit.

At the procedure visit, eligible patients were assigned the next available sequential patient number. By having a patient number assigned to them, patients were randomized to receive S-Caine Peel or placebo on the facial treatment area.

The surface area of the intended treatment area was determined (up to 200 cm2). A thin layer (approximately 1 mm or the thickness of a dime) of the study drug was applied evenly across the area to be treated. The study drug was applied for 20 minutes (±2 minutes).

Immediately following removal of the study drug, the investigator performed an evaluation of skin reactions, assessing the treatment area for erythema, edema and blanching or any other adverse skin reaction.

Study Timeline

• Study First Submitted: 2005-05-12
• Study First Submitted QC: 2005-05-12
• Study First Posted: 2005-05-13
• Study Start: 2005-06
• Primary Completion: 2005-10
• Study Completion: 2005-10
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-04
• Last Update Posted: 2012-06-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Patient is 18 years of age or older
• Patient elects to undergo PDL therapy for the treatment of vascular lesions on the face

Exclusion Criteria

• Patient is pregnant or breastfeeding
• Patient has participated in a clinical trial of an unapproved drug within the previous 30 days
• Patient has participated in any clinical trial involving S-Caine Peel

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
S-Caine Peel	S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)	-
Placebo Peel	Placebo Peel	-

Primary Outcome Measures

Name	Time	Method
Pain Intensity	20 minutes	Patient's evaluation of procedural pain intensity using the 100 mm Visual Analog Scale (VAS).

Secondary Outcome Measures

Name	Time	Method
Number of participants with adverse events	20 minutes	To monitor the nature and frequency of adverse events (AEs) associated with the application of S-Caine Peel

Trial Locations

Locations (3)

Washington Institute of Dermatologic Laser Surgery; 🇺🇸 Washington, District of Columbia, United States

Midwest Cutaneous Research; 🇺🇸 Clinton Township, Michigan, United States

Laser and Skin Surgery Center of New York; 🇺🇸 New York, New York, United States